Swedish Orphan Biovitrum registers Phase 3 trial of pegcetacoplan in kidney transplant recipients
The study, titled PRESERVE, plans to enroll 30 participants and has a planned start date of January 21, 2027. It aims to assess the efficacy and safety of pegcetacoplan for preventing recurrent C3G or primary IC-MPGN, with a planned primary completion date of January 17, 2031.
Primary source
ClinicalTrials.gov registry record, October 27, 2026
To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
Read the source: To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation